BR0114903A - 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação - Google Patents

7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação

Info

Publication number
BR0114903A
BR0114903A BR0114903-2A BR0114903A BR0114903A BR 0114903 A BR0114903 A BR 0114903A BR 0114903 A BR0114903 A BR 0114903A BR 0114903 A BR0114903 A BR 0114903A
Authority
BR
Brazil
Prior art keywords
phosphodiesterase
inhibitors
processes
preparation
application
Prior art date
Application number
BR0114903-2A
Other languages
English (en)
Inventor
Norbert Hoefgen
Ute Egerland
Thomas Kronbach
Degenhard Marx
Stefan Szelenyi
Hildegard Kuss
Emmanuel Polymeropoulos
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/de
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of BR0114903A publication Critical patent/BR0114903A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"7-AZAINDóIS, SUA APLICAçãO COMO INIBIDORES DA FOSFODIESTERASE 4 E PROCESSOS PARA A SUA PREPARAçãO". A invenção refere-se a novos 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação.
BR0114903-2A 2000-10-27 2001-10-25 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação BR0114903A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (de) 2000-10-27 2000-10-27 Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
US24434200P 2000-10-30 2000-10-30
PCT/EP2001/012376 WO2002034747A1 (de) 2000-10-27 2001-10-25 Neue 7-azaindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
BR0114903A true BR0114903A (pt) 2003-10-14

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114903-2A BR0114903A (pt) 2000-10-27 2001-10-25 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação

Country Status (28)

Country Link
US (3) US7169787B2 (pt)
EP (1) EP1330455B1 (pt)
JP (1) JP4233322B2 (pt)
KR (2) KR100837099B1 (pt)
CN (1) CN1247576C (pt)
AR (1) AR034269A1 (pt)
AT (1) ATE301121T1 (pt)
AU (2) AU2002221753B2 (pt)
BG (1) BG66169B1 (pt)
BR (1) BR0114903A (pt)
CA (1) CA2428468C (pt)
CZ (1) CZ20031146A3 (pt)
DE (1) DE50106993D1 (pt)
DK (1) DK1330455T3 (pt)
EE (1) EE05271B1 (pt)
ES (1) ES2246349T3 (pt)
HK (1) HK1053839A1 (pt)
HR (1) HRP20030427B1 (pt)
HU (1) HUP0303034A3 (pt)
IL (2) IL155386A0 (pt)
MX (1) MXPA03003624A (pt)
NO (1) NO324947B1 (pt)
NZ (1) NZ525369A (pt)
PL (1) PL213999B1 (pt)
PT (1) PT1330455E (pt)
SK (1) SK287774B6 (pt)
TW (1) TWI262920B (pt)
WO (1) WO2002034747A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
KR20090048520A (ko) * 2002-11-06 2009-05-13 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1786813A2 (en) * 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP2865381A1 (en) 2006-05-18 2015-04-29 Pharmacyclics, Inc. ITK inhibitors for treating blood cell malignancies
EP2058310A4 (en) 2006-09-01 2010-11-17 Kyorin Seiyaku Kk PYRAZOLOPYRIDINCARBOXYL ACID AMID DERIVATIVE AND THE DERIVATIVELY PHOSPHODIESTERASE (PDE) INHIBITOR
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
ES2478289T3 (es) * 2008-09-22 2014-07-21 Isis Innovation Ltd Bisfosfonatos de 5-azaindol
US8816085B2 (en) * 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
WO2012072727A1 (en) * 2010-12-03 2012-06-07 Biotie Therapies Gmbh Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
WO2012080329A1 (en) * 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
CN102584842A (zh) * 2011-01-17 2012-07-18 北京大学 取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
CN113679717A (zh) 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
EP3107902B1 (en) * 2014-02-20 2021-04-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Compounds and methods for inhibiting fascin
EP3863638B1 (en) * 2018-10-12 2024-06-26 Board of Regents of the University of Nebraska Phosphodiesterase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) * 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
JP3775684B2 (ja) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
AU672224B2 (en) 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
JP3119758B2 (ja) * 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
DE69532238T2 (de) 1994-04-21 2004-10-21 Schering Ag Pde iv-inhibitoren zur behandlung der multiplen sklerose
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (ja) 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
AUPO282996A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
CA2366615A1 (en) * 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
US20040106641A1 (en) 2004-06-03
DE50106993D1 (de) 2005-09-08
HUP0303034A3 (en) 2012-12-28
AU2002221753B2 (en) 2006-12-14
CN1484644A (zh) 2004-03-24
US20060258700A1 (en) 2006-11-16
HRP20030427A2 (en) 2003-08-31
ES2246349T3 (es) 2006-02-16
US7169787B2 (en) 2007-01-30
EE05271B1 (et) 2010-02-15
HK1053839A1 (en) 2003-11-07
CZ20031146A3 (cs) 2003-10-15
EP1330455A1 (de) 2003-07-30
IL155386A (en) 2008-06-05
KR20030065499A (ko) 2003-08-06
US20080207680A1 (en) 2008-08-28
NO20031722D0 (no) 2003-04-14
CA2428468A1 (en) 2002-05-02
PL213999B1 (pl) 2013-06-28
KR100880586B1 (ko) 2009-01-30
NO20031722L (no) 2003-04-14
BG107725A (bg) 2004-08-31
EE200300166A (et) 2003-08-15
AU2175302A (en) 2002-05-06
EP1330455B1 (de) 2005-08-03
US7683074B2 (en) 2010-03-23
PT1330455E (pt) 2005-10-31
CA2428468C (en) 2011-06-14
NO324947B1 (no) 2008-01-07
TWI262920B (en) 2006-10-01
ATE301121T1 (de) 2005-08-15
JP4233322B2 (ja) 2009-03-04
AR034269A1 (es) 2004-02-18
PL362837A1 (en) 2004-11-02
KR100837099B1 (ko) 2008-06-13
DK1330455T3 (da) 2005-12-05
CN1247576C (zh) 2006-03-29
JP2004512337A (ja) 2004-04-22
NZ525369A (en) 2004-09-24
SK287774B6 (sk) 2011-09-05
US7419987B2 (en) 2008-09-02
MXPA03003624A (es) 2004-12-02
HUP0303034A2 (hu) 2003-12-29
SK5092003A3 (en) 2004-08-03
HRP20030427B1 (en) 2006-04-30
IL155386A0 (en) 2003-11-23
BG66169B1 (bg) 2011-10-31
KR20080016758A (ko) 2008-02-21
WO2002034747A1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CR7728A (es) Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
ID23374A (id) Halogenopirimidin
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ITTO20000779A0 (it) Composizioni farmaceutiche.
HN2001000281A (es) Nuevas imidazotriazinonas sustituidas
MA25996A1 (fr) Inhibiteurs de phosphodiesterase 4.
SE0301653D0 (sv) Novel compounds
SE9802729D0 (sv) Novel Compounds
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
ATE330017T1 (de) Kallikrein gen
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
BR9913389B1 (pt) agentes de preparaÇço, bem como precesso para sua preparaÇço.
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
BR0116205A (pt) 2-piridonas antimicrobianas, suas composições e usos
UY26556A1 (es) Compuestos calcilíticos
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
ID27733A (id) Metoksiminofenilasetamida
BR0101437A (pt) Método para preparar um ciclopropeno
BR9810407A (pt) Compostos fluormetoximino
ATE275551T1 (de) Halogenpyrimidine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ELBION GMBH (DE)

Free format text: NOME ALTERADO DE: ELBION AG

B25D Requested change of name of applicant approved

Owner name: BIOTIE THERAPIES GMBH (DE)

Free format text: NOME ALTERADO DE: ELBION GMBH

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 471/04, A61P 11/00, A61K 31/40

Ipc: C07D 471/04 (2006.01), A61K 31/40 (2006.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.